With 28 member states and associated countries, initiating a clinical trial in the EU is perceived by many in the industry to be a daunting challenge. Upcoming changes in the regulations will change the clinical trial approval process, and make it much easier for pharma and biotech companies.
Objectives of the session:
- Understand the current scenario for including European site(s) in your clinical trials;
- Anticipate and plan for future changes and their impact on the overall approval process and timeline.